GlassScriptPhysician profile
Edwin Laserna Fuentes
NPI 1053360966
$1,163.85
in general payments reported to CMS, 2019-2025
30 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.76 · 2022: $622 · 2023: $393 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $139.70 | 2022-2025 | Austedo Xr |
| Alexion Pharmaceuticals, INC. | $69.92 | 2022-2023 | Ultomiris |
| Neurocrine Biosciences, INC. | $66.16 | 2022 | |
| Lundbeck LLC | $66.06 | 2022-2023 | Vyepti |
| Argenx US, INC. | $61.26 | 2022-2023 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $58.27 | 2022-2023 | |
| Abbvie INC. | $56.03 | 2022-2023 | |
| Eisai INC. | $52.48 | 2022 | |
| Merck Sharp & Dohme LLC | $52.09 | 2022 | |
| Amgen INC. | $50.46 | 2022-2023 | Aimovig |
| Boston Scientific Corporation | $44.69 | 2022-2023 | |
| Ucb, INC. | $41.90 | 2022-2023 | Nayzilam |
| Collegium Pharmaceutical, INC. | $39.93 | 2022-2023 | Xtampza |
| Impel Pharmaceuticals INC. | $35.86 | 2022-2023 | Trudhesa |
| Acadia Pharmaceuticals INC | $34.31 | 2023 | Nuplazid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $32.91 | 2022-2023 | Valtoco |
| Lilly USA, LLC | $30.53 | 2022 | |
| Emd Serono, INC. | $28.80 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $23.27 | 2022 | |
| Genzyme Corporation | $19.34 | 2022 | |
| Avanir Pharmaceuticals, INC. | $18.85 | 2022 | |
| Amneal Pharmaceuticals LLC | $18.49 | 2023 | Lyvispah |
| Adamas Pharmaceuticals, INC. | $17.53 | 2021 | |
| Currax Pharmaceuticals LLC | $17.52 | 2023 | Onzetra Xsail |
| Banner Life Sciences, LLC | $16.43 | 2022 | |
| Corium, LLC | $16.41 | 2023 | Adlarity |
| Otsuka America Pharmaceutical, INC. | $15.37 | 2023 | Nuedexta |
| Aprecia Pharmaceuticals, LLC | $13.40 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.15 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.73 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Fuentes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.